Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESImmunotherapy has played an integral role in oncology research for more than a century, but in the last few years we’ve seen extraordinary discoveries that are transforming the way we think about cancer treatment. New advances in immunotherapies including cancer vaccines, CAR T-Cell Therapies, PD-1/PD-L1 inhibitors, and other therapies and diagnostics are transforming the standard of care and significantly improving survival rates for these patients.
This transformation is exciting for industry, but it is adding a lot of complexity to the drug development process that sponsors, CROs and investigative sites need to address. Delivering targeted immunotherapies to market requires more sophisticated site selection, and monitoring and oversight processes particularly in early phase trials in which changing standards of care and multiple arms can easily overwhelm site staff adding time, cost and risk to the trial process.
But it doesn’t have to be overwhelming. When sponsors and CROs address the following five challenges they can mitigate many of the risks that come with these trials and increase the ease with which they bring these treatments to market.
Immuno-oncology research is a constantly changing science, and every new discovery has the potential to impact related ongoing trials. For example, FDA’s approval of nivolumab and pembrolizumab, which are both PD-1 inhibitors, changed the standard of care for non-small cell lung cancer (NSCLC). If a sponsor was running a third-line study after those drugs were approved, the trial might suddenly become difficult to recruit.
To increase site’s adaptability, studies should be designed for flexibility to better enable changes midstream. This includes having pre-defined processes in place to quickly amend protocols, communicate changes to site teams, and reallocate human and capital resources as necessary. It also requires a robust education program for site monitors and investigators to keep them fully up to date on changing safety signals, including evolving toxicity management guidelines, and the importance of tracking immuno-related events as evidence of progression.